Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals
- 14 July 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (29) , 34540-34553
Abstract
Therapeutically relevant proteins naturally adsorb to interfaces, causing aggregation which in turn potentially leads to numerous adverse consequences such as loss of activity or unwanted immunogenic reactions. Surfactants are ubiquitously used in biotherapeutics drug development to oppose interfacial stress, yet, the choice of the surfactant is extremely limited: to date, only polysorbates (PS20/80) and poloxamer 188 are used in commercial products. However, both surfactant families suffer from severe degradation and impurities of the raw material, which frequently increases the risk of particle generation, chemical protein degradation, and potential adverse immune reactions. Herein, we assessed a total of 40 suitable alternative surfactant candidates and subsequently performed a selection through a three-gate screening process employing four protein modalities encompassing six different formulations. The screening is based on short-term agitation-induced aggregation studies coupled to particle analysis and surface tension characterization, followed by long-term quiescence stability studies connected to protein purity measurements and particle analysis. The study concludes by assessing the surfactant's chemical and enzymatic degradation propensity. The candidates emerging from the screening are de novo α-tocopherol-derivatives named VEDG-2.2 and VEDS, produced ad hoc for this study. They display protein stabilization potential comparable or better than polysorbates together with an increased resistance to chemical and enzymatic degradation, thus representing valuable alternative surfactants for biotherapeutics.Keywords
Funding Information
- Novartis
This publication has 51 references indexed in Scilit:
- Protein Effects on Surfactant Adsorption Suggest the Dominant Mode of Surfactant-Mediated Stabilization of ProteinJournal of Pharmaceutical Sciences, 2014
- Differential Effects of Commercial-Grade and Purified Poloxamer 188 on Renal FunctionDrugs in R&D, 2014
- Modulation of Protein Adsorption by Poloxamer 188 in Relation to Polysorbates 80 and 20 at Solid SurfacesJournal of Pharmaceutical Sciences, 2014
- Immunogenicity of therapeutic proteins: Influence of aggregationJournal of Immunotoxicology, 2013
- Protein–excipient interactions: Mechanisms and biophysical characterization applied to protein formulation developmentAdvanced Drug Delivery Reviews, 2011
- Molecular origins of surfactant-mediated stabilization of protein drugsAdvanced Drug Delivery Reviews, 2011
- Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and HydrolysisJournal of Pharmaceutical Sciences, 2011
- Protein aggregation—Pathways and influencing factorsInternational Journal of Pharmaceutics, 2010
- Tuning the Extent of Chiral Amplification by Temperature in a Dynamic Supramolecular PolymerJournal of the American Chemical Society, 2009
- Hierarchical Growth of Chiral Self-Assembled Structures in Protic MediaJournal of the American Chemical Society, 2000